

PHARMACEUTICAL 2023

## Olema Pharmaceuticals Inc. Rank 98 of 446









PHARMACEUTICAL 2023



## RealRate

Olema Pharmaceuticals Inc. Rank 98 of 446

The relative strengths and weaknesses of Olema Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Olema Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 98% points. The greatest weakness of Olema Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 200%, being 157% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	208,899
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,549
Liabilities, Non-Current	1,550
Other Assets	5,266
Other Compr. Net Income	-1,664
Other Expenses	0
Other Liabilities	0
Other Net Income	2,201
Other Revenues	0
Property and Equipment	1,480
Research and Development	82,274
Selling, General and Administrative Expense	24,714

Output Variable	Value in 1000 USD
Assets	215,645
Liabilities	18,099
Expenses	106,988
Revenues	0
Stockholders Equity	197,546
Net Income	-104,787
Comprehensive Net Income	-105,619
Economic Capital Ratio	200%

